Navigation Links
Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
Date:1/24/2012

CULVER CITY, Calif., Jan. 24, 2012 /PRNewswire/ -- Sofie Biosciences, Inc., offering a comprehensive range of products from pre-clinical PET imaging systems to new PET molecular imaging probes to better understand human disease, has been told that a U.S. Patent (8,101,740) will be granted by the United States Patent Office on technology that has been exclusively licensed to Sofie. The patent covers a family of novel PET probes, known as [18F]FAC.

Positron Emission Tomography (PET) is a molecular imaging technology that utilizes minute amounts of labeled molecules ("probes") to target and measure biological and pharmacological processes. Basic scientists can use the same probes to examine cells and mice, as physicians do in patients to visualize and characterize the biology of disease, monitor its progression, and evaluate therapeutic efficacy.

Basic and clinical scientists at UCLA invented this novel PET probe, [18F]FAC, which was created by a slight modification of the drug molecule, gemcitabine, one of the most common drugs for cancer.  Cancer cells lack the normal checks and balances to limit cell growth.  [18F]FAC provides an in vivo imaging assay of cell growth known as the DNA salvage pathway.  Tumors use the salvage pathway to provide high rates of DNA replication for their uncontrolled growth of cells containing malignant instructions.

[18F]FAC measures the enzyme, dCK, which controls the rate of DNA production through the salvage pathway. Cancer drugs like gemcitabine use dCK to convert the drug into a pharmacologically active product that blocks the high rates of DNA replication for growth of malignant cells, and induces DNA damage in cancer cells. One of Sofie's objectives with [18F]FAC is to use PET imaging to allow physicians the means to search throughout the body for tumors that will respond to drugs that target dCK (like gemcitabine and other drugs), thus enabling more patient-specific treatment selection.

Cells of the immune system also use the salvage pathway to replicate activated immune cells in response to pathogens in the body and show differential uptake of [18F]FAC when they are activated. Such a non-invasive imaging test could help physicians more effectively examine and measure the activity of immune system throughout the body.

"[18F]FAC is a remarkable imaging probe. It specifically targets a single enzyme, dCK, and when that target is removed, the signal is absent. [18F]FAC displays rapid in vivo transport into cells, dCK dependent accumulation, sufficient in vivo stability, and because of trace amounts of [18F]FAC used, no evidence has been found for neither pharmacologic effects nor the toxicity in humans. Making [18F]FAC available for broad use in both academic and commercial research communities is the next step in the milestones of the imaging probe segment of Sofie's business," said Patrick Phelps, Sofie's President and CEO. The instrumentation arm of Sofie provides technologies for [18F]FAC production and pre-clinical PET imaging to facilitate and simplify the use of [18F]FAC and other PET imaging probes in academic and commercial research.

Sofie has obtained an exclusive license from The Regents of the University of California. Three investigational new drug (IND) applications have been approved for [18F]FAC and two analogs, and clinical trials have been initiated. 

About Sofie Biosciences
Sofie is combining new PET imaging agents with innovative imaging systems to provide researchers and physicians with tools to better investigate the biology of disease. By empowering a wide array of people with valuable, translational imaging tools, Sofie is making PET scans more accessible and increasing the diversity of its applications.

For additional information, contact Dr. Jennifer Cho at 424.223.6948 or jennifer.cho@sofiebio.com.


'/>"/>
SOURCE Sofie Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sofie Biosciences is Awarded a DOE Phase I SBIR to Commercialize Microscale Radiochemistry Platform
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
5. Milestone Biosciences, LLC Further Strengthens Executive Management Team
6. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
7. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
8. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
9. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
10. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
11. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
Breaking Biology News(10 mins):